Jazz Hits A High Note With Luvox Resubmissions

FDA has accepted complete response to “approvable” on Solvay’s Luvox CR, putting U.S. commercialization partner Jazz a step closer to market with the extended-release fluvoxamine formulation.

More from Archive

More from Pink Sheet